The Additional Polycyclo Ring System Contains A 1,3-diazole [e.g., Bis (benzimidazol-2-yl) Stilene, Etc.] Patents (Class 548/305.4)
-
Patent number: 9200145Abstract: The present invention relates to a coupling agent for rubber/carbon black, containing a sulfide compound represented by the following chemical formula (I): (in the formula, each A represents O, S, NH or NR; each R represents a linear or branched alkyl or alkenyl group having 1 to 6 carbon atoms, or a cyclic alkyl or alkenyl group having 3 to 6 carbon atoms, and when A is NR, the plurality of R's on a condensed aromatic heterocyclic ring may be the same as or different from each other; n represents an integer from 1 to 6; and x represents an integer from 1 to 4).Type: GrantFiled: July 20, 2012Date of Patent: December 1, 2015Assignee: SHIKOKU CHEMICALS CORPORATIONInventors: Yukiharu Shirakawa, Takeshi Masuda
-
Patent number: 9101669Abstract: Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.Type: GrantFiled: January 31, 2012Date of Patent: August 11, 2015Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sei Kwang Hahn, Kimoon Kim, Hyuntae Jung, Jeong-A Yang, Kyeng Min Park
-
Publication number: 20150137084Abstract: Triptycene derivatives having symmetric or asymmetric substituents are provided. The triptycene derivatives of the present invention may be applied in phosphorescent lighting devices ranging from deep blue to red and may be applied as a host material, an electron transporting material or a hole transporting material. An OLED device is also herein disclosed.Type: ApplicationFiled: May 19, 2014Publication date: May 21, 2015Applicant: National Tsing Hua UniversityInventors: Chien-Hong CHENG, Ho-Hsiu CHOU, Cheng-Chang LAI
-
Publication number: 20150123089Abstract: The present application provides a new nitrogen-containing heterocyclic compound and an organic electronic device using the same.Type: ApplicationFiled: April 12, 2013Publication date: May 7, 2015Inventors: Dong Hoon Lee, Tae Yoon Park, Sung Kil Hong, Boonjae Jang, Minseung Chun, Dong Sik Kim, Minyoung Kang
-
Publication number: 20150090963Abstract: An organic compound represented by Formula 1 is disclosed. An organic light-emitting device including the organic compound is also disclosed.Type: ApplicationFiled: February 25, 2014Publication date: April 2, 2015Applicant: SAMSUNG DISPLAY CO., LTD.Inventors: Young-Kook Kim, Kwang-Hyun Kim, Eun-Young Lee
-
Patent number: 8993778Abstract: A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1?-methylbenzimidazol-2?-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4?-[2?-n-propyl-4?-methyl-6?-(1??-methylbenzimidazol-2??-yl)benzimidazol-1?-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.Type: GrantFiled: January 25, 2013Date of Patent: March 31, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Norbert Hauel, Rolf Dach, Helmut Heitger, Oliver Meyer
-
Patent number: 8952177Abstract: The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X1, X1?, X1?, R1, R2 and R3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: March 13, 2014Date of Patent: February 10, 2015Assignee: Janssen Pharmaceutica NVInventors: Wenying Chai, Curt A. Dvorak, Wendy Eccles, James P. Edwards, Steven D. Goldberg, Paul J. Krawczuk, Alec D. Lebsack, Jing Liu, Daniel J. Pippel, Zachary S. Sales, Virginia M. Tanis, Mark S. Tichenor, John J. M. Wiener
-
Publication number: 20150031884Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Type: ApplicationFiled: December 15, 2011Publication date: January 29, 2015Applicant: ABBVIE INC.Inventors: Allan C. Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
-
Publication number: 20150024321Abstract: To provide an azo compound which improves the dispersibility of an azo pigment in a non-water soluble solvent. The purpose is achieved by an azo compound having a specific structure in which a high molecular weight polymer unit is bonded.Type: ApplicationFiled: February 20, 2013Publication date: January 22, 2015Inventors: Masanori Seki, Yuki Hasegawa, Waka Hasegawa, Masashi Kawamura, Taiki Watanabe, Chiaki Nishiura, Takayuki Toyoda, Ayano Mashida, Yasuaki Murai, Masashi Hirose
-
Publication number: 20140364616Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Type: ApplicationFiled: December 15, 2011Publication date: December 11, 2014Applicant: ABBVIE INC.Inventors: Allan C. Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
-
Publication number: 20140343286Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.Type: ApplicationFiled: December 15, 2011Publication date: November 20, 2014Inventors: Allan C. Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
-
Publication number: 20140316144Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: June 26, 2014Publication date: October 23, 2014Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, John O. Link, Teresa Alejandra Trejo Martin
-
Patent number: 8859780Abstract: The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.Type: GrantFiled: December 27, 2012Date of Patent: October 14, 2014Assignee: Allergan, Inc.Inventors: George R. Ehring, Ellen Chao, Herman Ng, Hau Ton, Jia Chian Li, Joseph S. Adorante, Michael S. Garst, Howard B. Rind, Mark R. Hansen, Alfred Arthur Avey, Jr., Lloyd Jay Dolby, Shervin Esfandiari, Vivian R. MacKenzie, Jeremiah Andrew Marsden, David Charles Muchmore
-
Publication number: 20140284584Abstract: Disclosed herein are compounds represented by the formula: where HT and n are defined herein. Compositions of said compounds along with organic light-emitting diode (OLED) devices related thereto are also disclosed.Type: ApplicationFiled: March 25, 2014Publication date: September 25, 2014Applicant: NITTO DENKO CORPORATIONInventor: Shijun Zheng
-
Publication number: 20140243257Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B?, X, Y, R1, R1?, R2, R2?, R3, R3?, R5, R5?, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventors: James A. Henderson, John Maxwell, Louis Vaillancourt, Mark Morris, Ronald Grey, JR., Simon Giroux, Laval Chan Chun Kong, Sanjoy Kumar Das, Bingcan Liu, Carl Poisson, Caroline Cadilhac, Monica Bubenik, T. Jagadeeswar Reddy, Guy Falardeau, Constantin Yannopoulos, Jian Wang, Oswy Z. Pereira, Youssef L. Bennani, Albert C. Pierce, Govinda Rao Bhisetti, Kevin M. Cottrell, Valerie Marone
-
Publication number: 20140231715Abstract: The present invention relates to a compound of the formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).Type: ApplicationFiled: March 23, 2012Publication date: August 21, 2014Applicant: Merck Patent GmbH Patents & Scientific InformationInventors: Philipp Stoessel, Arne Buesing, Frank Voges, Christof Pflumm, Amir Hossain Parham, Thomas Eberle, Teresa Mujica-Fernaud
-
Patent number: 8809313Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.Type: GrantFiled: May 29, 2012Date of Patent: August 19, 2014Assignee: Achillion Pharmaceuticals, Inc.Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
-
Patent number: 8779156Abstract: Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B?, X, Y, R1, R2, R2?, R3, R3?, R4, R4?, R5, R5?, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.Type: GrantFiled: September 24, 2012Date of Patent: July 15, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Sanjoy Kumar Das, Youssef L. Benanni, Laval Chan Chun Kong, John Maxwell, T. Jagadeeswar Reddy, Constantin Yannopoulos, Bingcan Liu, Caroline Cadilhac, Simon Giroux, James A. Henderson, Real Denis, Louis Vaillancourt, Oswy Z. Pereira, Carl Poisson, Guy Falardeau, Mark A. Morris
-
Patent number: 8765731Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B?, X, Y, R1, R1?, R2, R2?, R3, R3?, R5, R5?, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.Type: GrantFiled: November 16, 2012Date of Patent: July 1, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: James A. Henderson, John Maxwell, Louis Vaillancourt, Mark Morris, Ronald Grey, Jr., Simon Giroux, Laval Chan Chun Kong, Sanjoy Kumar Das, Bingan Liu, Carl Poisson, Caroline Cadilhac, Monica Bubenik, T. Jagadeeswar Reddy, Guy Falardeau, Constantin Yannopoulos, Jian Wang, Oswy Z. Pereira, Youssef L. Bennani, Albert C. Pierce, Govinda Rao Bhisetti, Kevin M. Cottrell, Valerie Marone
-
Publication number: 20140163237Abstract: Some embodiments provide a compound represented by Formula 1: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are independently H, C1-C3 alkyl, or C1-3 perfluoroalkyl; HT is optionally substituted carbazoyl, optionally substituted phenylcarbazolyl, optionally substituted (phenylcarbazolyl)phenyl, optionally substituted phenylnaphthylamine, or optionally substituted diphenylamine; and ET optionally substituted benzimidazol-2-yl, optionally substituted benzothiazol-2-yl, optionally substituted benzoxazol-2-yl, optionally substituted 3,3?-bipyridin-5-yl, optionally substituted quinolin-8-yl, optionally substituted quinolin-5-yl, or optionally substituted quinoxalin-5-yl. Other embodiments provide an organic light-emitting diode device comprising a compound of Formula 1.Type: ApplicationFiled: December 10, 2013Publication date: June 12, 2014Applicant: NITTO DENKO CORPORTIONInventors: David T. Sisk, Shijun Zheng
-
Publication number: 20140155541Abstract: The present invention relates to a coupling agent for rubber/carbon black, containing a sulfide compound represented by the following chemical formula (I): (in the formula, each A represents O, S, NH or NR; each R represents a linear or branched alkyl or alkenyl group having 1 to 6 carbon atoms, or a cyclic alkyl or alkenyl group having 3 to 6 carbon atoms, and when A is NR, the plurality of R's on a condensed aromatic heterocyclic ring may be the same as or different from each other; n represents an integer from 1 to 6; and x represents an integer from 1 to 4).Type: ApplicationFiled: July 20, 2012Publication date: June 5, 2014Applicant: SHIKOKU CHEMICALS CORPORATIONInventors: Yukiharu Shirakawa, Takeshi Masuda
-
Publication number: 20140135322Abstract: The present invention relates to novel chemical compounds formula (I) (C)n—B-(A)m-B—(C)n (I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five- and six-membered heteroaromatic rings, and for a terminal ring B or C also from bicyclic heteroaromatic fused rings having seven to ten ring members, wherein the bond between at least two of the rings A to C may be replaced by a carbonyl group (—CO—), wherein at least two of the rings A to C are substituted with one or two groups R, and wherein each ring A to C further optionally is substituted with one or two groups R1. The compounds are useful in therapy, especially therapy of a mammal suffering from a disease involving misfolded or aggregated forms of proteins.Type: ApplicationFiled: July 13, 2012Publication date: May 15, 2014Inventors: Peter Asberg, Kristin Hammer, Johan Olsson, Martin Henriksson
-
Publication number: 20140100245Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family is disclosed.Type: ApplicationFiled: November 27, 2013Publication date: April 10, 2014Applicant: SIGA TECHNOLOGIES, INC.Inventors: Dongcheng Dai, DENNIS E. HRUBY, TOVE C. BOLKEN, SEAN M. AMBERG, TRAVIS K. WARREN
-
Patent number: 8691999Abstract: An improved process for the preparation of telmisartan, or a pharmaceutically acceptable salt thereof, comprises subjecting 1H-Benzimidazole-2-n-propyl-4-methyl-6-(1?-methyl benzimidazole-2?yl)] of formula (II), and methyl-4-(bromomethyl)biphenyl-2-carboxylate of formula (III) to condensation and hydrolysis in a single step:Type: GrantFiled: May 10, 2005Date of Patent: April 8, 2014Assignee: Cipla LimitedInventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Srinivas Laxminarayan Pathi, Ravikumar Puppala
-
Patent number: 8623899Abstract: Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R? have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.Type: GrantFiled: August 6, 2010Date of Patent: January 7, 2014Assignee: Janssen Research & Development IrelandInventors: David McGowan, Samuel Dominique Demin, Stefaan Julien Last, Koen Vandyck, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 8623347Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family is disclosed.Type: GrantFiled: January 14, 2009Date of Patent: January 7, 2014Assignee: Siga Technologies, Inc.Inventors: Dongcheng Dai, Dennis E. Hruby, Tove C. Bolken, Sean M. Amberg, Travis K. Warren
-
Publication number: 20130317213Abstract: The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Inventors: Shawn K. Pack, Steven Tymonko, Bharat P. Patel, Kenneth J. Natalie, JR., Makonen Belema
-
Publication number: 20130317047Abstract: The present invention relates to use of an inhibitor of the renin-anglotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).Type: ApplicationFiled: November 9, 2012Publication date: November 28, 2013Applicant: Aventis Pharma Deutschland GmbHInventor: Aventis Pharma Deutschland GmbH
-
Publication number: 20130295049Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 30, 2012Publication date: November 7, 2013Applicant: ENANTA PHARMACEUTICALS, INCInventor: ENANTA PHARMACEUTICALS, INC
-
Patent number: 8563738Abstract: Ligands useful for promoting copper-catalyzed azide-alkyne cycloaddition reactions comprise a compound represented by structural Formula (I) as described in the specification, wherein in Formula (I) Z1 is a nitrogen-containing heterocyclic group or a group represented by the formula: Y1—(CH2)c—Y2—(CH2)d—Y3—CH2—N(CH2Z4)(CH2Z5), where Y1 is -E1-C(O)O—, -E1-C(O)NH—, -E1-, or a covalent bond; Y2 is a covalent bond, —CH?CH—, or a 1,4-(1,2,3-triazolyl) group; Y3 is —OC(O)-E2-, —NHC(O)-E2-, -E2-, or a covalent bond; each of E1 and E2 is a benzimidazolyl group attached at the 1 and 2 positions; each of c and d is independently 1, 2, 3, 4, or 5; each of Z2, Z3, Z4 and Z5 is a nitrogen-containing heterocyclic group including a substituent X1 and optionally including a substituent (CH2)n—R1, and Y1, Y2, Y3, X1, R1, c, d and n are each as defined in the specification.Type: GrantFiled: September 15, 2008Date of Patent: October 22, 2013Assignee: The Scripps Research InstituteInventors: M. G. Finn, Valentin O. Rodionov
-
Publication number: 20130190508Abstract: Novel N-heterocyclic carbene ligand precursors, N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are provided. Metal-carbene complexes comprising N-heterocyclic carbene ligands can be chiral, which are useful for catalyzing enantioselective synthesis. Methods for the preparation of the N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are given.Type: ApplicationFiled: March 8, 2013Publication date: July 25, 2013Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
-
Publication number: 20130190373Abstract: A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.Type: ApplicationFiled: March 13, 2013Publication date: July 25, 2013Applicant: Boehringer Ingelheim Vetmedica GmbHInventor: Boehringer Ingelheim Vetmedica GmbH
-
Publication number: 20130172570Abstract: This present invention provides a method of making benzazoles comprising a process of making aryl or alkyl benzazoles from corresponding aryl acid chlorides or alkyl acid chlorides without applying hazard condensing agent. The benzazole compounds described in this invention have following formula I: Wherein: n is an integer of from 3 to 8; Z is O, NR or S; and R and R? are individually hydrogen; alkyl of from 1 to 24 carbon atoms, for example, propyl, t-butyl, heptyl, and the like; aryl or hetero-atom substituted aryl of from 5 to 20 carbon atoms, for example, phenyl and naphthyl, furyl, thienyl, pyridyl, quinolinyl and other heterocyclic systems; or halo such as chloro, fluoro, bromo, cyano; or atoms necessary to complete a fused aromatic ring; and B is a linkage unit consisting of alkyl, aryl, substituted alkyl, or substituted aryl which conjugately or unconjugately connects the multiple benzazoles together.Type: ApplicationFiled: February 15, 2012Publication date: July 4, 2013Applicant: US Government as Represented by the Secretary of the ARMYInventors: Jianmin Shi, Eric W. Forsythe, David C. Morton
-
Publication number: 20130164258Abstract: The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient.Type: ApplicationFiled: May 28, 2010Publication date: June 27, 2013Inventors: Kevin X. Chen, Anilkumar Gopinadhan Nair, Qingbei Zeng, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
-
Publication number: 20130153874Abstract: Provided are an organic electroluminescence device, which: shows high luminous efficiency; is free of any pixel defect; and has a long lifetime, and a material for an organic electroluminescence device for realizing the device. The material for an organic electroluminescence device is a compound of a specific structure having a ?-conjugated heteroacene skeleton crosslinked with a carbon atom, nitrogen atom, or oxygen atom. The organic electroluminescence device has one or more organic thin film layers including a light emitting layer between a cathode and an anode, and at least one layer of the organic thin film layers contains the material for an organic electroluminescence device.Type: ApplicationFiled: February 5, 2013Publication date: June 20, 2013Applicant: IDEMITSU KOSAN CO., LTD.Inventor: IDEMITSU KOSAN CO., LTD.
-
Publication number: 20130157997Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B?, X, Y, R1, R1?, R2, R2?, R3, R3?, R5, R5?, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.Type: ApplicationFiled: November 16, 2012Publication date: June 20, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8461351Abstract: A sterically bulky stabilizer that includes an alkylated-benzimidazolone compound, where the sterically bulky stabilizer is associated non-covalently with a benzimidazolone pigment, and the presence of the sterically bulky stabilizer limits the extent of particle growth and aggregation, to afford nanoscale pigment particles.Type: GrantFiled: July 28, 2011Date of Patent: June 11, 2013Assignees: Xerox Corporation, National Research Council of CanadaInventors: Rina Carlini, Darren Andrew Makeiff
-
Publication number: 20130137878Abstract: A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1?-methylbenzimidazol-2?-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4?-[2?-n-propyl-4?-methyl-6?-(1??-methylbenzimidazol-2??-yl)benzimidazol-1?-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.Type: ApplicationFiled: January 25, 2013Publication date: May 30, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Norbert HAUEL, Rolf DACH, Helmut HEITGER, Oliver MEYER
-
Publication number: 20130126791Abstract: The present invention relates to a polymer which contains at least one structural unit which has electron-transport properties, to processes for the preparation thereof and to mixtures (blends), solutions and formulations which comprise these polymers. Furthermore, the present invention relates to the use of these polymers in electronic devices, in particular in organic electro-luminescent devices, so-called OLEDs (OLED=organic light emitting diodes), and to these organic electroluminescent devices themselves. The polymers according to the invention exhibit improved efficiency, in particular on use in OLEDs.Type: ApplicationFiled: July 8, 2011Publication date: May 23, 2013Applicant: Merck Patent GmbHInventors: Susanne Heun, Aurélie Ludemann, Rémi Manouk Anémian
-
Patent number: 8445693Abstract: One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3?-(2?-halo-biphenyl-4-ylmethyl)-1,7?-dimethyl-2?-propyl-1H,3?H-[2,5?]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.Type: GrantFiled: March 19, 2009Date of Patent: May 21, 2013Assignee: Lek Pharmaceuticals D.D.Inventors: Zdenko Casar, Anton Copar, Jerome Cluzeau, Andrej Premrl
-
Publication number: 20130115193Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: November 8, 2012Publication date: May 9, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Publication number: 20130112946Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein X1 and X2, X1 and R1 to R10 are defined as in the specification.Type: ApplicationFiled: February 29, 2012Publication date: May 9, 2013Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.Inventors: Bum-Woo Park, Yoon-Hyun Kwak, Sun-Young Lee, Chang-Ho Lee, Se-Jin Cho
-
Publication number: 20130105769Abstract: A condensed-cyclic compound represented by Formula 1, and an organic light-emitting device including the condensed-cyclic compound. wherein R1 and R2, Ar1 through Ar4, L1 and L2, X1 and X2, and a and b are defined as in the specification.Type: ApplicationFiled: May 22, 2012Publication date: May 2, 2013Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.Inventors: Jin-O Lim, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Sang-Hyun Han, Soo-Yon Kim, Hee-Joo Ko
-
Publication number: 20130102788Abstract: The present invention relates to efficient synthetic method of 1,3,5-tris (N-Phenylbenzimidazole) Benzene and pertains to the field of synthesis of organic light-emitting materials. The method and process of the patent are as following: 1,3,5-tris (N-Phenyl-N Phenylammonium) Benzamide is treated by shrinking agent but no high temperature required, and then high purity product can be reached after raw material dissolved. The reaction only takes a few minutes and through recrystallization the purity can be over 99%, and then the material with stable crystal phase reached after sublimation step. The method introduced by the present patent is easy to operate, and with high in yield and purity, which adapt industrial production and has important significance for the industrialization.Type: ApplicationFiled: February 9, 2011Publication date: April 25, 2013Applicants: BEIJING AGLAIA TECHNOLOGY DEVELOPMENT CO., LTD., GUANGDONG AGLAIA OPTOECTRONIC MATERIALS CO., LTD.Inventors: Lifei Cai, Lei Dai, Hongyu Zhao, Yanfeng Ding, Weilong Zhang, Junhao Lian
-
Patent number: 8410285Abstract: A process for obtaining 2?-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental mental halogen. In addition, the coupling of arised 2?-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1?-methylbenzimidazole-2-il)benzimidazole to afford 3?-(2?-halo-biphenyl-4-ylmethyl)-1,7?-dimethyl-2?-propyl-1H,3?H-[2,5?]bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described.Type: GrantFiled: March 19, 2009Date of Patent: April 2, 2013Assignee: LEK Pharmaceuticals D.D.Inventors: Anton Copar, Zdenko Casar, Andrej Premrl
-
Publication number: 20130066252Abstract: The invention relates to a method for diagnosis of multiple sclerosis (MS) wherein, presence or absence of an anti-AT1 receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease.Type: ApplicationFiled: April 12, 2011Publication date: March 14, 2013Applicant: CELLTREND GMBHInventor: Harald Heidecke
-
Publication number: 20130056075Abstract: Provided is a compound of formula (I): wherein A is C2-3 alkylene; m is an integer ranging from 2 to 25; and n is an integer ranging from 3 to 10. An electrolyte for a dye-sensitized solar cell having the compound of formula (I) and/or a compound of formula (II) is further provided for increasing photoelectric conversion efficiency.Type: ApplicationFiled: September 4, 2012Publication date: March 7, 2013Applicant: EVERLIGHT USA, INC.Inventors: Yu-Hui Lee, Hsin-Ying Lu, Kuan-Wei Lee, Tzu-Heng Ko
-
Publication number: 20130059852Abstract: Some embodiments of this invention include methods for treating disease and methods for administering a compound of Formula (I). In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of Formula (I). Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I).Type: ApplicationFiled: April 8, 2011Publication date: March 7, 2013Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: John O. Trent, Jason B. Meier, Kelby B. Napier
-
Publication number: 20130053558Abstract: The invention relates to compounds of the formula (1), to a method for producing compounds of the formula (1), to the use of the compounds in electronic devices and to electronic devices containing compounds according to formula (1), preferably as electron transport materials, as matrix materials, as electron blocking materials or as emitting materials.Type: ApplicationFiled: October 14, 2010Publication date: February 28, 2013Applicant: Merck Patent GmbHInventors: Christof Pflumm, Arne Buesing, Amir Hossain Parham, Rocco Fortte, Holger Heil, Philipp Stoessel, Teresa Mujica-Fernaud
-
Patent number: 8362269Abstract: The invention relates to a process for preparing 1,7?-dimethyl-2?-propyl-2,5?-bi-1H-benzimidazole of formula (I)Type: GrantFiled: April 29, 2009Date of Patent: January 29, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Richard Ehlenz, Oliver Meyer, Hartmut Schmidt